Cutaneous T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Cutaneous T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-03-25Clinical Trial Update: Immunization Against Tumor Cells in Sezary Syndrome [Phase 2]
Status update indicates the completion of a Phase 2 clinical trial evaluating an immunization against tumor cells in Sézary syndrome (cutane…
-
CLINICAL_TRIALS trial_result · 2015-03-23Clinical Trial Update: O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial assessed the combination of O6-Benzylguanine with topical Carmustine in patients with early-stage cutaneous T-cell lymphom…
-
CLINICAL_TRIALS trial_result · 2015-03-03Clinical Trial Update: RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluated everolimus (RAD001) in combination with CHOP chemotherapy for newly diagnosed peripheral T-cell lymphom…
-
CLINICAL_TRIALS withdrawal · 2015-01-26Clinical Trial Update: Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)
The document reports that the denileukin diftitox access program for patients currently receiving Ontak is no longer available. It signals a…
-
CLINICAL_TRIALS withdrawal · 2015-01-21Clinical Trial Update: Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma [Phase 3]
A Phase 3 trial evaluating vorinostat with or without bortezomib for refractory or recurrent cutaneous T-cell lymphoma has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-12-15Clinical Trial Update: Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 trial of vorinostat in primary cutaneous T-cell lymphoma was terminated; results posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-12-03Clinical Trial Update: Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating the combination of gemcitabine and bexarotene for progressive or refractory cutaneous T-cell lymphoma ha…
-
FDA approval · 2014-12-02FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for Targretin (bexarotene) submitted by Bausch Health US, LLC.
-
CLINICAL_TRIALS trial_result · 2014-10-27Clinical Trial Update: A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas [Phase 2]
A Phase II study of PXD101 (belinostat) in recurrent or refractory cutaneous T-cell lymphoma and peripheral T-cell lymphoma was terminated; …
-
FDA approval · 2014-10-15FDA Approved: ISTODAX — Supplemental Application (Celgene Corporation)
The FDA approved a Celgene supplemental application for ISTODAX (romidepsin).
-
FDA approval · 2014-08-12FDA Approved: BEXAROTENE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's generic bexarotene for use in cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome.
-
CLINICAL_TRIALS trial_result · 2014-08-04Clinical Trial Update: Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma [NA]
ClinicalTrials.gov provides an update on using Helical Irradiation of Total Skin (HITS) for treating Cutaneous T-cell Lymphoma. The current …
-
FDA approval · 2014-07-09FDA Approved: VALCHLOR — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for VALCHLOR (mechlorethamine hydrochloride) from Helsinn Therapeutics (U.S.), Inc.
-
CLINICAL_TRIALS research · 2014-05-28Clinical Trial Update: In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
An in vitro study from the University of Pittsburgh evaluates immune responses in cutaneous T-cell lymphoma, including Sézary syndrome and m…
-
CLINICAL_TRIALS trial_result · 2014-03-31Clinical Trial Update: Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a treatment for recalcitrant pruritus in patients with cutaneous T-cell lymphoma was terminated.
-
CLINICAL_TRIALS trial_result · 2013-12-18Clinical Trial Update: Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides [Phase 2]
This entry provides an update on a Phase 2 trial of combination chemotherapy for advanced or recurrent mycosis fungoides. Mycosis fungoides …
-
CLINICAL_TRIALS research · 2013-12-18Clinical Trial Update: Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma [Phase 2]
Phase 2 clinical trial investigating chemotherapy combined with photodynamic therapy for cutaneous T-cell lymphoma. The current trial status…
-
FDA approval · 2013-08-23FDA Approved: VALCHLOR — Original Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved VALCHLOR (mechlorethamine hydrochloride) gel in an original application for the treatment of mycosis fungoides, a type of cutan…
-
FDA approval · 2013-07-22FDA Approved: TARGRETIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for TARGRETIN (bexarotene) submitted by Bausch Health US, LLC.
-
CLINICAL_TRIALS trial_result · 2013-07-10Clinical Trial Update: Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma [Phase 1]
A Phase 1 clinical trial of Forodesine (BCX-1777) for patients with refractory cutaneous T-cell lymphoma (stages IIA, IIB, III, IVA, or IVB)…
-
FDA label_change · 2013-06-05FDA Approved: UVADEX — Supplemental Application (Therakos LLC)
FDA approved a supplemental application for UVADEX (methoxsalen) submitted by Therakos LLC, updating the product's labeling for its use in p…
-
CLINICAL_TRIALS trial_result · 2013-05-30Clinical Trial Update: BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial of BCX-1777 in patients with refractory cutaneous T-cell lymphoma has completed.
-
FDA approval · 2013-04-24FDA Approved: ZOLINZA — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for Zolinza (vorinostat) filed by Merck. The action updates the labeling and may reflect changes…
-
CLINICAL_TRIALS trial_result · 2013-04-04Clinical Trial Update: Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma [Phase 2]
A Phase 2 trial evaluating the combination of bexarotene and interferon alfa for cutaneous T-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating 506U78 for recurrent or refractory cutaneous T-cell lymphoma has been terminated.